Committee For the Protection of Human Subjects

Reporting Problems

POLICY

The Principal Investigator is responsible for the accurate documentation, investigation and follow-up and timely reporting of the following problems:

a.       Any adverse event which in the opinion of the principal investigator is both unexpected and related and places subjects or others at risk of harm.

b.      Information that indicates a change to the risks or potential benefits of the research. For example:

               i.      An interim analysis or safety monitoring report indicates that frequency or magnitude of harms or benefits may be different than initially presented to the IRB.

             ii.      A paper is published from another study that shows that the risks or potential benefits of the research may be different than initially presented to the IRB.

c.       A breach of confidentiality.

d.      Change in FDA labeling or withdrawal from marketing of a drug, device, or biologic used in a research protocol.

e.      Change to the protocol taken without prior IRB review to eliminate an apparent immediate hazard to a research participant.

f.        Incarceration of a participant in a protocol not approved to enroll prisoners

g.       Event that requires prompt reporting to the sponsor.

h.      Sponsor imposed suspension for risk.

i.         Complaint of a participant when the complaint indicates unexpected risks or cannot be resolved by the research team.

j.        Protocol deviation (meaning an accidental or unintentional change to the IRB approved protocol) that harmed participants or others or that indicates participants or others may be at increased risk of harm.

k.       Unanticipated adverse device effect

 

Key Terms

Adverse Event - Any undesirable and unintended, although not necessarily unexpected, effect of the research occurring in human subjects as a result of (a) the interventions and interactions used in the research; or (b) the collection of identifiable private information under the research.

An unanticipated adverse device effect as defined by FDA regulations at 2CFR 812.3(s) – Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

 

PROCEDURE

Assessment by Principal Investigator - The Principal Investigator must make a judgment about the expectedness of a problem. If the problem is an adverse event, the investigator must make a judgment about the causality of the adverse event. The Principal Investigator must also analyze the event and state whether protocol / consent form revisions are required.

 

Assessment of Expectedness - The Principal Investigator must state whether the problem is expected or unexpected. An unexpected problem is one, the nature and severity of which is not consistent with information in the relevant source document (s). For an investigational drug, the Investigator Brochure serves as the source document. Reports that add significant information on specificity or severity of a known, already documented serious adverse event constitute unexpected events. For example, a problem more specific or more severe than described in the Investigator’s Brochure would be considered unexpected.

 

Assessment of Causality – For adverse events the Principal Investigator should evaluate the event and assess causality. The expression ‘reasonable causal relationship’ is meant to convey in general that there are facts (evidence) or arguments to suggest a causal relationship. For purposes of reporting, adverse event reports associated with marketed drugs usually imply causality. The following conditions might help to assess causality:

a.       the event has a reasonable temporal relationship to the intervention,

b.      the event could not have been produced by the underlying disease states,

c.       the event could not have been due to other non-study interventions,

d.      the event follows a known pattern of response to the intervention, or

e.      the event disappears with cessation of intervention.

 

Reporting Timeframe

Investigators must report the reportable events described above to CPHS via iRIS within 7 days, unless the report involves the death of a participant, in which case the report needs to be provided to CPHS within 24 hours.

a.       All problems involving local deaths, should be reported immediately – within 24 hours after first knowledge by the investigator.

b.      All other problems must be reported as soon as possible but not later than 7 calendar days after first knowledge by the investigator.

 

CPHS Review Process

Upon receipt of reports, ORSC Staff will review them and determine if the report meets the following two criteria: (1) unexpected and (2) indicates that participants or others are at increased risk of harm.

a.       If the report does NOT meet both criteria, the report is NOT an unanticipated problem involving risks to participants or others, and no further action is taken.

b.      If the report meets both criteria, the report is an unanticipated problem involving risks to participants or others.

ORSC Staff will evaluate reports that meet the definition of unanticipated problems involving risks to subjects or others to determine if the problems involve more than minimal risk to subjects or others.

Unanticipated problems that involve no more than minimal risk to subjects or others may be reviewed by expedited procedure. ORSC Staff shall assign it for review by the Chairperson of the subcommittee that initially reviewed the research proposal. If the Chairperson is not available, the ORSC Staff will assign it to one of the other subcommittee members or another CPHS member.

ORSC Staff will include unanticipated problems involving greater than minimal risks to subjects or others in the agenda for the next full board meeting of the IRB that conducted the initial or previous continuing review of the research. Where possible, ORSC Staff shall assign it to the Chairperson of the subcommittee that initially reviewed the research. If the Chairperson is not available, ORSC Staff will assign it to one of the other subcommittee members or another CPHS member. The Reviewer and all CPHS members have access to all previous information regarding the research project in iRIS.

 

Outcome of Review: The convened IRB Panel considers the following actions:

a.       No action;

b.      Modification of research protocol;

c.       Modification of information disclosed during the consent process;

d.      Additional information provided to past subjects;

e.      Additional information provided to current subjects (required when such information may relate to subjects’ willingness to continue to take part in the research);

f.        Request the outcome of the most recent Data Safety Monitoring review;

g.       Requirement that current subjects re-consent to participation;

h.      Modification of the continuing review schedule;

i.         Monitoring of the research;

j.        Monitoring of the consent process;

k.       Suspension of the research;

l.         Termination of the research;

m.    More information sought pending final decision;

n.      Referral to appropriate institutional authorities such as legal counsel, Institutional Official

o.      Any other actions.

If CPHS requires the Principal Investigator to make more than minor modifications in response to unanticipated problems involving risks to subjects or others, the Principal Investigator’s modifications will be reviewed at the subsequent full board meeting as per policy and procedure Change Requests and Protocol Amendment.

 

Reporting: After review by the convened IRB, the unanticipated problem involving risks to participants or others is reported to regulatory agencies and institutional officials following policy and procedure on Reporting.

 

APPLICABLE REGULATIONS

1.                   45 CFR 46.103(b)(5)(i)

2.                   21 CFR 56.108(b)(1)

3.                   21 CFR 312.53(c)(vii)

4.                   21 CFR 312.66

5.                   21 CFR 812(a)(1)

6.                   OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

7.                   OHRP Guidance on Reporting Incidents to OHRP

8.                   FDA Information Sheets: Continuing Review After Study Approval

REFERENCE TO OTHER POLICIES

1.                   Change Request and Protocol Amendment

2.                   Reporting

ATTACHMENTS

1.                   Serious Internal Adverse Event Reporting Form

2.                   Unanticipated Problems Reporting Form

3.                   Miscellaneous Submission Form

4.                   Protocol Deviation Submission Form

If you find errors in this document, contact clinicaltrials@uth.tmc.edu

 

Document Number:

101-C13

Document Name:

Reporting Problems

Approved by:

ORSC Director

Effective:

1 Aug 2008

Revision History:

1 Jan 2009
1 Aug 2011


CPHS HELPLINE   713-500-7943
iRIS HELPLINE    713-500-7960
UTHealth’s Compliance Hotline (1-888-472-9868)

How can we improve this site?


Committee for the Protection of Human Subjects
6410 Fannin, Suite 1100
Houston, Texas 77030

Phone 713.500.7943
Fax     713.500.7951
Email cphs@uth.tmc.edu 

IRIS Support 713.500.7960

CLINICAL TRIALS RESOURCE CENTER 

OFFICE OF RESEARCH 

ENVIRONMENTAL HEALTH & SAFETY 

CORE LABORATORIES

SPONSORED PROJECTS

TECHNOLOGY MANAGEMENT


aahrpp logo